Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum

Clinical and Diagnostic Laboratory Immunology
Vera A SemenovaConrad P Quinn

Abstract

An anti-Anthrax Vaccine Adsorbed (anti-AVA) standard human reference serum pool, AVR414, has been prepared, and the total and protective antigen (PA)-specific immunoglobulin G (IgG) were quantified. AVR414 was prepared by plasmapheresis of healthy adults who had received a minimum of four subcutaneous injections of AVA. Mass values (in milligrams per milliliter) for total IgG and IgG subclasses 1 to 4 were determined by radial immunodiffusion. Anti-PA-specific IgG assignment (in micrograms per milliliter) was done by consensus of two complementary approaches: homologous enzyme-linked immunosorbent assay (ELISA) with affinity-purified anti-PA IgG as a calibrator and summation of mean PA-specific IgG subclass concentrations determined by IgG subclass-specific ELISA using the United States National Reference Preparation for Human Serum Proteins as a standard. The total IgG concentration assigned to AVR414 reference serum was 8.33 mg/ml. IgG subclass concentrations were the following: for IgG1, 4.48 mg/ml; for IgG2, 3.35 mg/ml; for IgG3, 0.37 mg/ml; and for IgG4, 0.30 mg/ml. The assigned mass value for total anti-PA-specific IgG was 141.2 microg/ml. Anti-PA-specific IgG subclass concentrations were the following: for IgG1, 79.6 mic...Continue Reading

References

Jan 1, 1987·International Archives of Allergy and Applied Immunology·T SöderströmL A Hanson
Oct 1, 1983·European Journal of Immunology·O Mäkelä, F Péterfy
Oct 1, 1994·Journal of Clinical Microbiology·B D PlikaytisG M Carlone
Aug 26, 1998·Revue Scientifique Et Technique·R H Jacobson
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·C Y WangC V Hanson
Dec 14, 1999·Microbes and Infection·S F Little, B E Ivins
Mar 29, 2000·Protein Expression and Purification·S Park, S H Leppla
Dec 12, 2001·Vaccine·P R PittmanA M Friedlander
Dec 19, 2001·Emerging Infectious Diseases·J A JerniganUNKNOWN Anthrax Bioterrorism Investigation Team
Oct 25, 2002·Emerging Infectious Diseases·Daniel B JerniganUNKNOWN National Anthrax Epidemiologic Investigation Team
Oct 25, 2002·Emerging Infectious Diseases·Marc S TraegerUNKNOWN Florida Investigation Team
Oct 25, 2002·Emerging Infectious Diseases·Puneet K DewanUNKNOWN Washington, D.C., Anthrax Response Team
Oct 28, 2003·The American Journal of Pathology·Wun-Ju ShiehUNKNOWN Anthrax Bioterrorism Investigation Team

❮ Previous
Next ❯

Citations

Jun 3, 2005·Analytical and Bioanalytical Chemistry·R E BiaginiC P Quinn
Jul 28, 2012·Vector Borne and Zoonotic Diseases·Jennifer AdjemianDavid Wong
Sep 14, 2012·Science Translational Medicine·Michael P FayEdwin O Nuzum
Dec 26, 2012·Biologicals : Journal of the International Association of Biological Standardization·Jarad M SchifferConrad P Quinn
Sep 30, 2010·Biologicals : Journal of the International Association of Biological Standardization·Stephen D SorokaConrad P Quinn
Jul 6, 2006·Virology·Mary Ellen SmithMatthias J Schnell
Nov 7, 2016·Biologicals : Journal of the International Association of Biological Standardization·Vera A SemenovaJarad Schiffer
Feb 13, 2016·Clinical and Vaccine Immunology : CVI·Conrad P QuinnJennifer G Wright
Apr 18, 2008·Clinical and Vaccine Immunology : CVI·Kristian S OmlandUNKNOWN Participating Laboratories
Jun 9, 2005·Clinical and Diagnostic Laboratory Immunology·Phillip R PittmanKelly T McKee
Jan 26, 2007·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Henri C van der HeydeJohn P Nolan
Jan 20, 2009·Nature Biotechnology·Yoshimi KuroiwaJames M Robl
Jul 28, 2019·Nanomedicine : Nanotechnology, Biology, and Medicine·Amir BolandparvazJamal S Lewis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.